Kymriah

New approval sets up CAR-T showdown for Gilead, Novartis
New approval sets up CAR-T showdown for Gilead, Novartis
Biopharma Dive
Kymriah
Novartis
cell therapy
Yescarta
Gilead Sciences
Flag link:
ICER declares costs of approved CAR-T therapies aligned with clinical benefit
ICER declares costs of approved CAR-T therapies aligned with clinical benefit
BioWorld
CAR-T
ICER
Gilead Sciences
Yescarta
Novartis
Kymriah
drug pricing
Flag link:
Novartis’ Kymriah: The First Gene Therapy to Be Approved in the US
Novartis’ Kymriah: The First Gene Therapy to Be Approved in the US
Market Realist
Novartis
Kymriah
gene therapy
acute lymphoblastic leukemia
Flag link:
Novartis could cut its Kymriah price to $160,000 and keep its profit margins: study
Novartis could cut its Kymriah price to $160,000 and keep its profit margins: study
Fierce Pharma
Novartis
Kymriah
pricing
Flag link:
Patient Advocate Says Novartis' $475,000 Breakthrough Should Cost Just $160,000
Patient Advocate Says Novartis' $475,000 Breakthrough Should Cost Just $160,000
Forbes
Novartis
drug pricing
Kymriah
Flag link:
Top 10 stories that had pharma execs talking
Top 10 stories that had pharma execs talking
Biopharma Dive
M&A
Bristol-Myers Squibb
Opdivo
Express Scripts
Novartis
C-ART
Kymriah
Massachusetts
AbbVie
Kenneth Frazier
biosimilars
CVS Health Pfizer
Flag link:
Kymriah, Yescarta found ‘cost-effective’ in treating cancer, despite high price
Kymriah, Yescarta found ‘cost-effective’ in treating cancer, despite high price
Endpoints
Kymriah
Yescarta
CAR-T
Novartis
Kite Pharma
Gilead Sciences
drug pricing
Flag link:
ASH 2017: CAR-T Wallops Blood Cancer
ASH 2017: CAR-T Wallops Blood Cancer
Motley Fool
ASH2017
CAR-T
gene therapy
Novartis
Kymriah
Yescarta
Gilead Sciences
Juno Therapeutics
JCAR017
Flag link:
#ASH17: How does Novartis’ Kymriah DLBCL data stack up heading straight to a CAR-T showdown with Gilead?
#ASH17: How does Novartis’ Kymriah DLBCL data stack up heading straight to a CAR-T showdown with Gilead?
Endpoints
ASH17
Novartis
Kymriah
DLBCL
CAR-T
diffuse large B-cell lymphoma
Flag link:
Incoming Novartis CEO On $475,000 Cancer Therapy: 'No Question That The List Price Raises Eyebrows'
Incoming Novartis CEO On $475,000 Cancer Therapy: 'No Question That The List Price Raises Eyebrows'
Forbes
Novartis
drug pricing
cancer
Kymriah
Pharma CEOs
Vas Narasimhan
Flag link:
Novartis seeks European approval for cell therapy Kymriah
Novartis seeks European approval for cell therapy Kymriah
Reuters
Novartis
Europe
CAR-T
Kymriah
diffuse large B-cell lymphoma
acute lymphoblastic leukemia
Flag link:
Novartis hustles along another FDA application for CAR-T star, tackling Gilead head on
Novartis hustles along another FDA application for CAR-T star, tackling Gilead head on
Endpoints
Novartis
FDA
CAR-T
Kymriah
diffuse large B-cell lymphoma
Flag link:
Here Come More Gene Therapies -- And More Pricing Debates
Here Come More Gene Therapies -- And More Pricing Debates
Forbes
gene therapies
drug pricing
Luxturna
Spark Therapeutics
Kymriah
Novartis
Flag link:
Big Pharma Doesn't Want Health Outcomes To Sway Pricing -- At Least Not Yet
Big Pharma Doesn't Want Health Outcomes To Sway Pricing -- At Least Not Yet
Forbes
Big Pharma
drug pricing
gene therapy
Novartis
Kymriah
Flag link:
Premium price for Novartis' CAR-T sparks pushback from top PBM
Premium price for Novartis' CAR-T sparks pushback from top PBM
BioPharma Dive
Novartis
Kymriah
CAR-T
drug pricing
Express Scripts
PBMs
Flag link:
Express Scripts' Miller Backs New Pricing Models for CAR-T
Express Scripts' Miller Backs New Pricing Models for CAR-T
BioCentury
Express Scripts
drug pricing
CAR-T
gene therapy
Kymriah
Flag link:
At $475,000, new cancer drug raises thorny questions about drug pricing — and value
At $475,000, new cancer drug raises thorny questions about drug pricing — and value
Stat
drug pricing
CAR-T
Novartis
Kymriah
Flag link:
Landmark approval won, Novartis' next test is scaling CAR-T manufacturing
Landmark approval won, Novartis' next test is scaling CAR-T manufacturing
BioPharma Dive
Novartis
CAR-T
Kymriah
FDA
drug manufacturing
Flag link:
Profit on $475,000 Novartis cancer drug could be a while coming
Profit on $475,000 Novartis cancer drug could be a while coming
Yahoo/Reuters
Novartis
CAR-T
Kymriah
Flag link:
Why bluebird bio Inc Continued Its March Higher Again Today
Why bluebird bio Inc Continued Its March Higher Again Today
Motley Fool
Bluebird Bio
bb2121
CAR-T
Novartis
Kymriah
Gilead Sciences
Kite Pharma
Flag link:

Pages